ROIV (Roivant Sciences) Tariff Resilience Score: 8/10 (As of Jun. 29, 2026)


ROIV Roivant Sciences Ltd ROIV
55 GF Score
Price $34.60
GF Value $10.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Tariff Resilience Score?

Roivant Sciences ROIV +1.56% 55 Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $10.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,375 Biotechnology companies, Roivant Sciences ranks better than 98.69% on this metric.

Roivant Sciences has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Roivant Sciences has Roivant Sciences Ltd has minimal exposure to tariffs as it operates primarily in the pharmaceutical sector, which often benefits from tariff exemptions. The company's supply chain is less globalized, and it has strong pricing power in its niche markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Roivant Sciences might have Highly Resilient.

Roivant Sciences  (NAS:ROIV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Roivant Sciences Tariff Resilience Score Related Terms

ROIV vs RPRX, BNTX, INCY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Roivant Sciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Tariff Resilience Score falls into.


ROIV
55GF Score
Roivant Sciences Ltd ROIV
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Roivant Sciences (ROIV) has a Tariff Resilience Score of 8 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Roivant Sciences ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Roivant Sciences' Tariff Resilience Score too high?
Roivant Sciences' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Roivant Sciences' value of 8 is 100% above this industry median. Based on the distribution chart, Roivant Sciences ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Tariff Resilience Score compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #18 out of 1375 companies for Tariff Resilience Score. This places Roivant Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Roivant Sciences' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $34.60 — trading 231.1% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $34.60 is trading 231.1% above its estimated GF Value™ of $10.45. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Tariff Resilience Score: 8
  • GF Value™: $10.45 vs. price of $34.60 (231.1% above fair value)
  • GF Score™: 55/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1375)

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIV

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.60
Price
$10.45
GF Value